|
1
|
Hogg SJ, Beavis PA, Dawson MA and
Johnstone RW: Targeting the epigenetic regulation of antitumour
immunity. Nat Rev Drug Discov. 19:776–800. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feinberg AP, Koldobskiy MA and Göndör A:
Epigenetic modulators, modifiers and mediators in cancer aetiology
and progression. Nat Rev Genet. 17:284–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Strahl BD and Allis CD: The language of
covalent histone modifications. Nature. 403:41–45. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JM, Hammarén HM, Savitski MM and Baek
SH: Control of protein stability by post-translational
modifications. Nat Commun. 14:2012023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diallo I, Seve M, Cunin V, Minassian F,
Poisson JF, Michelland S and Bourgoin-Voillard S: Current trends in
protein acetylation analysis. Expert Rev Proteomics. 16:139–159.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Zhang R and Hei H: Advances in
post-translational modifications of proteins and cancer
immunotherapy. Front Immunol. 14:12293972023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wesche J, Kühn S, Kessler BM, Salton M and
Wolf A: Protein arginine methylation: A prominent modification and
its demethylation. Cell Mol Life Sci. 74:3305–3315. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Q, Schapira M, Arrowsmith CH and
Barsyte-Lovejoy D: Protein arginine methylation: From enigmatic
functions to therapeutic targeting. Nat Rev Drug Discov.
20:509–530. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Y and Bedford MT: Protein arginine
methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang L, Ma DW, Cao YP, Li DZ, Zhou X, Feng
JF and Bao J: PRMT5 functionally associates with EZH2 to promote
colorectal cancer progression through epigenetically repressing
CDKN2B expression. Theranostics. 11:3742–3759. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stopa N, Krebs JE and Shechter D: The
PRMT5 arginine methyltransferase: Many roles in development, cancer
and beyond. Cell Mol Life Sci. 72:2041–2059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoxhaj G and Manning BD: The PI3K-AKT
network at the interface of oncogenic signalling and cancer
metabolism. Nat Rev Cancer. 20:74–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu A, Yu C, Qiu C, Wu Q, Huang C, Li X,
She X, Wan K, Liu L, Li M, et al: PRMT5 methylating SMAD4 activates
TGF-β signaling and promotes colorectal cancer metastasis.
Oncogene. 42:1572–1584. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang JH, Wang WT, Wang R, Gao R, Du KX,
Duan ZW, Zhang XY, Li Y, Wu JZ, Yin H, et al: PRMT5 activates lipid
metabolic reprogramming via MYC contributing to the growth and
survival of mantle cell lymphoma. Cancer Lett. 591:2168772024.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu X, Fernando TM, Lossos C, Yusufova N,
Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, et al: PRMT5
interacts with the BCL6 oncoprotein and is required for germinal
center formation and lymphoma cell survival. Blood. 132:2026–2039.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng K, Chen S, Ren Z and Wang Y: Protein
arginine methylation in viral infection and antiviral immunity. Int
J Biol Sci. 19:5292–5318. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu K, Peng Y, Hu J, Zhan H, Yang L, Gao
Q, Jia H, Luo R, Dai Z, Tang Z, et al: Metadherin-PRMT5 complex
enhances the metastasis of hepatocellular carcinoma through the
WNT-beta-catenin signaling pathway. Carcinogenesis. 41:130–138.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang F, Song P, Xiao Z, Su R, Fang X, Wu
Y, Xu X and Wang K: PRMT5 promotes pancreatic cancer tumorigenesis
via positive PRMT5/C-Myc feedback loop. MedComm (2020).
6:e701502025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan Y, Zhao P, Wang Z, Liu Z, Wang Z,
Zhang J, Ding Y, Hua X and Yu L: PRMT5 regulates colorectal cancer
cell growth and EMT via EGFR/Akt/GSK3β signaling cascades. Aging
(Albany NY). 13:4468–4481. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ge L, Wang H, Xu X, Zhou Z, He J, Peng W,
Du F, Zhang Y, Gong A and Xu M: PRMT5 promotes
epithelial-mesenchymal transition via EGFR-β-catenin axis in
pancreatic cancer cells. J Cell Mol Med. 24:1969–1979. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qin Y, Hu Q, Xu J, Ji S, Dai W, Liu W, Xu
W, Sun Q, Zhang Z, Ni Q, et al: PRMT5 enhances tumorigenicity and
glycolysis in pancreatic cancer via the FBW7/cMyc axis. Cell Commun
Signal. 17:302019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng BN, Ding CH, Chen SJ, Zhu K, Shao J,
Feng J, Xu WP, Cai LY, Zhu CP, Duan W, et al: Targeting PRMT5
activity inhibits the malignancy of hepatocellular carcinoma by
promoting the transcription of HNF4α. Theranostics. 9:2606–2617.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu M, Yao B, Gui T, Guo C, Wu X, Li J, Ma
L, Deng Y, Xu P, Wang Y, et al: PRMT5-dependent transcriptional
repression of c-Myc target genes promotes gastric cancer
progression. Theranostics. 10:4437–4452. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan Y, Zhao P, Wang Z, Liu Z, Wang Z,
Zhang J, Ding Y, Hua X and Yu L: PRMT5 regulates colorectal cancer
cell growth and EMT via EGFR/Akt/GSK3β signaling cascades. Aging
(Albany NY). 13:4468–4481. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yin S, Liu L, Brobbey C, Palanisamy V,
Ball LE, Olsen SK, Ostrowski MC and Gan W: PRMT5-mediated arginine
methylation activates AKT kinase to govern tumorigenesis. Nat
Commun. 12:34442021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abumustafa W, Castven D, Becker D, Salih
SS, Manzoor S, Zamer BA, Talaat I, Hamad M, Marquardt JU and
Muhammad JS: Inhibition of PRMT5-mediated regulation of DKK1
sensitizes colorectal cancer cells to chemotherapy. Cell Signal.
119:1111662024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu F, Guo H, Bates PD, Zhang S, Zhang H,
Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, et al: PRMT5 is
upregulated by B-cell receptor signaling and forms a
positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia.
33:2898–2911. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang L, Zhang XO, Rozen EJ, Sun X, Sallis
B, Verdejo-Torres O, Wigglesworth K, Moon D, Huang T, Cavaretta JP,
et al: PRMT5 activates AKT via methylation to promote tumor
metastasis. Nat Commun. 13:39552022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu R, Gao J, Yang Y, Qiu R, Zheng Y,
Huang W, Zeng Y, Hou Y, Wang S, Leng S, et al: PHD finger protein 1
(PHF1) is a novel reader for histone H4R3 symmetric dimethylation
and coordinates with PRMT5-WDR77/CRL4B complex to promote
tumorigenesis. Nucleic Acids Res. 46:6608–6626. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu D, Jia H, Zhang Z and Li S: Circ-PRMT5
promotes breast cancer by the miR-509-3p/TCF7L2 axis activating the
PI3K/AKT pathway. J Gene Med. 23:e33002021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chung J, Karkhanis V, Baiocchi RA and Sif
S: Protein arginine methyltransferase 5 (PRMT5) promotes survival
of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β
proliferative signaling. J Biol Chem. 294:7692–7710. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yuan Y and Nie H: Protein arginine
methyltransferase 5: A potential cancer therapeutic target. Cell
Oncol (Dordr). 44:33–44. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meng S, Liu H, Xu J, Deng C, Qian X, Chu
S, Zhu WG, Zhu J, Yong H, Li Z and Bai J: PRMT5-Mediated ALKBH5
methylation promotes colorectal cancer immune evasion via
increasing CD276 expression. Research (Wash D C).
8:05492025.PubMed/NCBI
|
|
34
|
Meirson T, Gil-Henn H and Samson AO:
Invasionmetastasis: The elusive hallmark of cancer. Oncogene.
39:2024–2026. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Q, Geng W, Guo H, Wang Z, Xu K, Chen
C and Wang S: Emerging role of RNA methyltransferase METTL3 in
gastrointestinal cancer. J Hematol Oncol. 13:572020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim H and Ronai ZeA: PRMT5 function and
targeting in cancer. Cell Stress. 4:199–215. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tanaka Y, Nagai Y, Okumura M, Greene MI
and Kambayashi T: PRMT5 is required for T cell survival and
proliferation by maintaining cytokine signaling. Front Immunol.
11:6212020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Quillien A, Gilbert G, Boulet M, Ethuin S,
Waltzer L and Vandel L: Prmt5 promotes vascular morphogenesis
independently of its methyltransferase activity. PLoS Genet.
17:e10096412021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Slade D: PARP and PARG inhibitors in
cancer treatment. Genes Dev. 34:360–394. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu Y, Xia T, Chen DQ, Xiong X, Shi L, Zuo
Y, Xiao H and Liu L: Promising role of protein arginine
methyltransferases in overcoming anti-cancer drug resistance. Drug
Resist Updat. 72:1010162024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu J, Fu S, Zou X, Zeng H, Cui G, Peng Y,
Tang D, Zhang F, Shen H, Zeng S and Han Y: PRMT5 inhibitor
synergizes with chemotherapy to induce resembling mismatch repair
deficiency and enhance Anti-TIGIT therapy in microsatellite-stable
colorectal cancer. Adv Sci (Weinh). 12:e25002712025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gillespie MS, Chiang K, Regan-Mochrie GL,
Choi SY, Ward CM, Sahay D, Garcia P, Arnold R and Davies CC:
PRMT5-regulated splicing of DNA repair genes drives chemoresistance
in breast cancer stem cells. Oncogene. 44:862–876. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lu L, Li H, Yin H, Wang F, Sun X, Chang Y,
Sheng Y, Liu Q, Peng Y and Du C: The expression of PRMT5 is
associated with postoperative chemotherapeutic outcome in colon
cancer. BMC Cancer. 25:7602025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gong L, Wu L, Zhao S, Xiao S, Chu X, Zhang
Y, Li F, Li S, Yang H and Jiang P: Epigenetic regulation of
ferroptosis in gastrointestinal cancers (Review). Int J Mol Med.
55:932025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tang MX, Chen JF, Zhao FZ and Peng J:
Ferroptosis: A critical link to treatment resistance in esophageal
carcinoma. iScience. 28:1129012025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hanahan D and Weinberg Robert A: Hallmarks
of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liang C, Zhang X, Yang M and Dong X:
Recent progress in ferroptosis inducers for cancer therapy. Adv
Mater. 31:e19041972019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sanderson SM, Gao X, Dai Z and Locasale
JW: Methionine metabolism in health and cancer: A nexus of diet and
precision medicine. Nat Rev Cancer. 19:625–637. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Heske CM: Beyond energy metabolism:
Exploiting the additional roles of NAMPT for cancer therapy. Front
Oncol. 9:15142020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu L, Zhao X, Zhao L, Li J, Yang H, Zhu
Z, Liu J and Huang G: Arginine Methylation of SREBP1a via PRMT5
promotes de novo lipogenesis and tumor growth. Cancer Res.
76:1260–1272. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yuan HF, Zhao M, Zhao LN, Yun HL, Yang G,
Geng Y, Wang YF, Zheng W, Yuan Y, Song TQ, et al: PRMT5 confers
lipid metabolism reprogramming, tumour growth and metastasis
depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in
tumours. Acta Pharmacol Sin. 43:2373–2385. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim KH, Jia Z, Snyder M, Chen J, Qiu J,
Oprescu SN, Chen X, Syed SA, Yue F, Roseguini BT, et al: PRMT5
links lipid metabolism to contractile function of skeletal muscles.
EMBO Rep. 24:e573062023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang N, Li T, Liu W, Lin J, Zhang K, Li Z,
Huang Y, Shi Y, Xu M and Liu X: USP7- and PRMT5-dependent G3BP2
stabilization drives de novo lipogenesis and tumorigenesis of HNSC.
Cell Death Dis. 14:1822023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chang X, Liu X, Wang H, Yang X and Gu Y:
Glycolysis in the progression of pancreatic cancer. Am J Cancer
Res. 12:861–872. 2022.PubMed/NCBI
|
|
57
|
Lytle NK, Barber AG and Reya T: Stem cell
fate in cancer growth, progression and therapy resistance. Nat Rev
Cancer. 18:669–680. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Caglar HO and Biray Avci C: Alterations of
cell cycle genes in cancer: Unmasking the role of cancer stem
cells. Mol Biol Rep. 47:3065–3076. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Williams ED, Gao D, Redfern A and Thompson
EW: Controversies around epithelial-mesenchymal plasticity in
cancer metastasis. Nat Rev Cancer. 19:716–732. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chiang K and Davies CC: Linking PRMT5 to
breast cancer stem cells: New therapeutic opportunities? Mol Cell
Oncol. 5:e14416282018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chiang K, Zielinska AE, Shaaban AM,
Sanchez-Bailon MP, Jarrold J, Clarke TL, Zhang J, Francis A, Jones
LJ, Smith S, et al: PRMT5 is a critical regulator of breast cancer
stem cell function via histone methylation and FOXP1 expression.
Cell Rep. 21:3498–3513. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi
W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L,
Rastegar N, et al: PRMT5 inhibition disrupts splicing and stemness
in glioblastoma. Nat Commun. 12:9792021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wei TY, Juan CC, Hisa JY, Su LJ, Lee YC,
Chou HY, Chen JM, Wu YC, Chiu SC, Hsu CP, et al: Protein arginine
methyltransferase 5 is a potential oncoprotein that upregulatesG1
cyclins/cyclin-dependent kinases and the phosphoinositide
3-kinase/AKTsignaling cascade. Cancer Sci. 103:1640–1650. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yang L, Li X, Shi C and Zhao B: Prmt5 is
essential for intestinal stem cell maintenance and homeostasis.
Cell Regen. 14:52025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu X, Tu C, Yang H, Tang B, Ye Y and Wang
H: PRMT5-FOXM1 axis activates β-catenin/IL8 signaling to drive
angiogenesis of gastric cancer. Cell Signal. 134:1119252025.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Scoumanne A, Zhang J and Chen X: PRMT5 is
required for cell-cycle progression and p53 tumor suppressor
function. Nucleic Acids Res. 37:4965–4976. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li L, Zhang Z, Wang X, Zhao H, Liu L, Xiao
Y, Hua S and Chen YG: PRMT5 Maintains homeostasis of the intestinal
epithelium by modulating cell proliferation and survival. Adv Sci
(Weinh). 12:e24155592025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Vieito M, Moreno V, Spreafico A, Brana I,
Wang JS, Preis M, Hernández T, Genta S, Hansen AR, Doger B, et al:
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase
5 inhibitor, in advanced solid tumors. Clin Cancer Res.
29:3592–3602. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li B, Yu JQ, Yang Z and Wang Y: PRMT5: A
promising synthetical lethal target for MTAP-deleted cancers. J Med
Chem. 68:18143–18163. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Rodon J, Prenen H, Sacher A,
Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N,
Ghiringhelli F, Goebeler ME, et al: First-in-human study of AMG
193, an MTA-cooperative PRMT5 inhibitor, in patients with
MTAP-deleted solid tumors: Results from phase I dose exploration.
Ann Oncol. 35:1138–1147. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Feustel K and Falchook GS: Protein
arginine methyltransferase 5 (PRMT5) inhibitors in oncology
clinical trials: A review. J Immunother Precis Oncol. 5:58–67.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sun J, Yuan H, Sun L, Zhao L, Wang Y, Hou
C, Zhang H, Lv P, Yang G, Zhang N, et al: Tumor-intrinsic PRMT5
upregulates FGL1 via methylating TCF12 to inhibit CD8+
T-cell-mediated antitumor immunity in liver cancer. Acta Pharm Sin
B. 15:188–204. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jiang K, Yin X, Zhang Q, Yin J, Tang Q, Xu
M, Wu L, Shen Y, Zhou Z, Yu H and Yan S: STC2 activates PRMT5 to
induce radioresistance through DNA damage repair and ferroptosis
pathways in esophageal squamous cell carcinoma. Redox Biol.
60:1026262023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cho EC, Zheng S, Munro S, Liu G, Carr SM,
Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, et al:
Arginine methylation controls growth regulation by E2F-1. EMBO J.
31:1785–1797. 2012. View Article : Google Scholar : PubMed/NCBI
|
